Quantcast

Latest Par Pharmaceutical Companies Inc. Stories

2014-09-30 08:31:42

WOODCLIFF LAKE, N.J., Sept. 30, 2014 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that it has begun shipping all four strengths of amlodipine and valsartan tablets, the generic version of Novartis' Exforge(®). Par received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for amlodipine and valsartan and was granted 180 days of marketing exclusivity. Amlodipine and valsartan is indicated for the treatment of...

2014-09-08 12:29:49

WOODCLIFF LAKE, N.J., Sept. 8, 2014 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that it has resumed shipping dexmedetomidine hydrochloride (HCl) injection, EQ 100 mcg base/mL, the generic version of Hospira's Precedex(®) Injection. Par immediately resumed shipping after a U.S. District Court lifted a temporary restraining order that was issued in August at Hospira's request. Last month, Par received final approval from the U.S. Food and Drug Administration...

2014-08-06 12:28:54

WOODCLIFF LAKE, N.J., Aug. 6, 2014 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. announced today that it will host a conference call on Wednesday, August 13, 2014 at 10:00 a.m. EDT to review its results of operations for the second quarter ended June 30, 2014. Par is privately held and currently makes certain financial information available to the public in its filings with the Securities and Exchange Commission. Par will file its financial statements for the quarter ended June...

2014-07-09 08:27:55

WOODCLIFF LAKE, N.J., July 9, 2014 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for fluphenazine decanoate injection, USP 25 mg/mL. Fluphenazine decanoate injection is a long-acting parenteral antipsychotic drug intended for use in the management of patients requiring prolonged parenteral neuroleptic therapy (e.g., chronic schizophrenics)....

2014-06-10 16:26:32

One Spray per Device, Without the Need for Priming, Provides Greater Ease of Use WOODCLIFF LAKE, N.J., June 10, 2014 /PRNewswire/ -- Strativa Pharmaceuticals, the branded division of Par Pharmaceutical Companies, Inc., today announced that the U.S. Food and Drug Administration has approved Nascobal(®) Nasal Spray in a single-use device. Nascobal(®) is a prescription vitamin B(12) supplement administered as one spray, one nostril, once a week. Each single-use device delivers one...

2014-05-07 12:30:29

WOODCLIFF LAKE, N.J., May 7, 2014 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. announced today that it will host a conference call on Friday, May 16, 2014 at 9:30 a.m. EDT to review its results of operations for the first quarter ended March 31, 2014. Par is privately held and currently makes certain financial information available to the public in its filings with the Securities and Exchange Commission. Par will file its financial statements for the quarter ended March 31,...

2014-04-07 12:33:20

WOODCLIFF LAKE, N.J., April 7, 2014 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for potassium chloride extended-release (ER) capsules, USP, in 600 mg (8 mEq K) and 750 mg (10 mEq K) strengths. Potassium chloride ER is indicated for the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxications, in...

2014-04-01 08:29:32

WOODCLIFF LAKE, N.J., April 1, 2014 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that Terrance J. Coughlin has been named chief operating officer. In this capacity, Mr. Coughlin will be responsible for Par's global manufacturing activities, research and development efforts and will be instrumental in the new product selection process. Mr. Coughlin joins Par from Glenmark Generics, Inc. USA/Glenmark Generics Limited where he most recently served as president...

2014-03-13 16:27:14

WOODCLIFF LAKE, N.J., March 13, 2014 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. announced today that it will host a conference call on Thursday, March 20, 2014 at 10:00 a.m. EDT to review its results of operations for the fourth quarter and full year ended December 31, 2013. Par is privately held and currently makes certain financial information available to the public in its filings with the Securities and Exchange Commission. Par will file its financial statements for...

2014-01-16 16:23:43

WOODCLIFF LAKE, N.J., Jan. 16, 2014 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that it has entered into an exclusive U.S. supply and distribution agreement with Covis Pharma S.a.r.l. to distribute the authorized generic version of Covis's Lanoxin(®) (digoxin) Tablets. The Lanoxin(®) brand has been relied upon for its quality and availability for more than 50 years. Digoxin tablets are indicated for treatment of mild to moderate heart failure in adults;...


Word of the Day
ambsace
  • Bad luck; misfortune.
  • The smallest amount possible or the most worthless thing.
The word 'ambsace' comes from a Latin word meaning 'both'.